Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MLG007
MIFTS: 33

Malignant Skin Fibrous Histiocytoma

Categories: Cancer diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways
Sources

Aliases & Classifications for Malignant Skin Fibrous Histiocytoma

About this section

MalaCards integrated aliases for Malignant Skin Fibrous Histiocytoma:

Name: Malignant Skin Fibrous Histiocytoma 12 15
Vaginal Melanoma 12 17 71
Malignant Fibrous Histiocytoma of Skin 12 71

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1906
NCIt 50 C5576
SNOMED-CT 67 404014008
UMLS 71 C1275254 C2004576
Sources

Summaries for Malignant Skin Fibrous Histiocytoma

About this section
MalaCards based summary : Malignant Skin Fibrous Histiocytoma, also known as vaginal melanoma, is related to mucosal melanoma and melanoma. An important gene associated with Malignant Skin Fibrous Histiocytoma is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and DAG and IP3 signaling. Affiliated tissues include skin, cervix and lymph node, and related phenotypes are craniofacial and integument

Sources

Related Diseases for Malignant Skin Fibrous Histiocytoma

About this section

Diseases related to Malignant Skin Fibrous Histiocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 mucosal melanoma 29.0 NRAS KIT IFNA2 GNAQ GNA11
2 melanoma 29.0 NRAS MLANA KIT IFNA2 HRAS GNAQ
3 vulvar melanoma 28.8 NRAS MLANA KIT HRAS GNAQ GNA11
4 skin melanoma 28.4 NRAS MLANA KIT IFNA2 HRAS GNAQ
5 melanoma, uveal 28.4 NRAS MLANA KIT HRAS GNAQ GNA11
6 malignant conjunctival melanoma 28.2 NRAS MLANA IFNA2 HRAS GNAQ GNA11
7 ovarian melanoma 10.2 NRAS MLANA
8 sensory organ benign neoplasm 10.2 NRAS MLANA
9 benign perivascular tumor 10.2 MLANA KIT
10 small intestine leiomyoma 10.2 MLANA KIT
11 skin sarcoma 10.2 MLANA KIT
12 mucinous stomach adenocarcinoma 10.2 MLANA KIT
13 retroperitoneal sarcoma 10.2 MLANA KIT
14 glomangiomatosis 10.2 MLANA KIT
15 vagina sarcoma 10.2 MLANA KIT
16 thymus clear cell carcinoma 10.2 MLANA KIT
17 uterus leiomyosarcoma 10.2 MLANA KIT
18 uterine corpus sarcoma 10.2 MLANA KIT
19 epithelioid cell melanoma 10.2 MLANA GNA11
20 retroperitoneum carcinoma 10.2 MLANA KIT
21 bladder sarcoma 10.2 MLANA KIT
22 kidney benign neoplasm 10.2 MLANA KIT
23 acneiform dermatitis 10.2 NRAS HRAS
24 perivascular epithelioid cell tumor 10.1 MLANA KIT
25 malignant fibrous histiocytoma 10.1
26 fibrous histiocytoma 10.1
27 oculoectodermal syndrome 10.1 NRAS HRAS
28 large intestine adenocarcinoma 10.1 NRAS HRAS
29 amelanotic melanoma 10.1 MLANA KIT
30 melanocytic nevus syndrome, congenital 10.1 NRAS HRAS
31 rare tumor 10.1
32 benign struma ovarii 10.1 NRAS HRAS
33 nasal cavity adenocarcinoma 10.1 MLANA HRAS
34 nasal cavity cancer 10.1 MLANA HRAS
35 spermatocytoma 10.1 KIT HRAS
36 conjunctival pigmentation 10.1 MLANA IFNA2
37 anus cancer 10.1 KIT HRAS
38 mesenchymal cell neoplasm 10.1 MLANA KIT
39 uterine body mixed cancer 10.1 KIT HRAS
40 vaginal discharge 10.1
41 connective tissue benign neoplasm 10.0 MLANA KIT
42 mixed cell type cancer 10.0 KIT HRAS
43 ras-associated autoimmune leukoproliferative disorder 10.0 NRAS HRAS
44 sarcomatoid renal cell carcinoma 10.0 KIT IFNA2
45 respiratory system benign neoplasm 10.0 MLANA HRAS
46 core binding factor acute myeloid leukemia 10.0 NRAS KIT HRAS
47 vulvar disease 10.0 NRAS KIT HRAS
48 acral lentiginous melanoma 10.0 NRAS KIT HRAS
49 myelodysplastic/myeloproliferative neoplasm 10.0 NRAS KIT HRAS
50 childhood acute myeloid leukemia 10.0 NRAS KIT HRAS

Graphical network of the top 20 diseases related to Malignant Skin Fibrous Histiocytoma:



Diseases related to Malignant Skin Fibrous Histiocytoma
Sources

Symptoms & Phenotypes for Malignant Skin Fibrous Histiocytoma

About this section

MGI Mouse Phenotypes related to Malignant Skin Fibrous Histiocytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.55 GNA11 GNAQ HRAS KIT NRAS
2 integument MP:0010771 9.43 GNA11 GNAQ HRAS KIT MLANA NRAS
3 pigmentation MP:0001186 9.02 GNA11 GNAQ KIT MLANA NRAS
Sources

Drugs & Therapeutics for Malignant Skin Fibrous Histiocytoma

About this section

Search Clinical Trials , NIH Clinical Center for Malignant Skin Fibrous Histiocytoma

Sources

Genetic Tests for Malignant Skin Fibrous Histiocytoma

About this section
Sources

Anatomical Context for Malignant Skin Fibrous Histiocytoma

About this section

MalaCards organs/tissues related to Malignant Skin Fibrous Histiocytoma:

40
Skin, Cervix, Lymph Node
Sources

Publications for Malignant Skin Fibrous Histiocytoma

About this section

Articles related to Malignant Skin Fibrous Histiocytoma:

(show top 50) (show all 125)
# Title Authors PMID Year
1
Imaging Studies in a Primary Vaginal Melanoma Disguised as a Suburethral Cyst: A Case Report. 61
33208656 2021
2
The role of sentinel lymph node mapping in lower genital tract melanoma. 61
32744452 2020
3
Mutational Profile in Vulvar, Vaginal, and Urethral Melanomas: Review of 37 Cases With Focus on Primary Tumor Site. 61
31567539 2020
4
Persistent vaginal melanoma as an unusual mimic in the endocervix. 61
33261829 2020
5
Malignant Melanoma of the Female Genital Tract: Experience of an Oncology Center in Pakistan. 61
32642388 2020
6
Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients. 61
31784896 2020
7
Primary malignant melanomas of the female lower genital tract: clinicopathological characteristics and management. 61
33414983 2020
8
Primary malignant melanoma of the uterine cervix or vagina which were successfully treated with nivolumab. 61
31608533 2020
9
Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report. 61
31737773 2019
10
Primary vaginal malignant melanoma: A rare entity with review of literature. 61
31898678 2019
11
Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma. 61
31279873 2019
12
Melanoma of the Vulva and Vagina: Surgical Management and Outcomes Based on a Clinicopathologic Reviewof 68 Cases. 61
30391279 2019
13
Response to imatinib in vaginal melanoma with KIT p.Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab. 61
30614559 2019
14
Amelanotic primary vaginal melanoma: A case report with cyto-histological correlations. 61
30478998 2019
15
Feasibility of Carbon Ion Radiotherapy in the Treatment of Gynecological Melanoma. 61
30804128 2019
16
Pigmented Conjunctival Lesions as Presenting Signs of Vaginal Melanoma. 61
30320085 2018
17
[Primary malignant melanoma of vagina]. 61
30113785 2018
18
Primary Vaginal Melanoma With Rhabdoid Features: A Case Report and Literature Review. 61
28800579 2017
19
Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. 61
28026870 2017
20
A retrospective clinical analysis of 5 cases of vaginal melanoma. 61
28451415 2017
21
Cytology of primary vaginal melanoma: An unusual report on fine needle aspiration. 61
27863187 2017
22
Primary Vaginal Melanoma, A Rare and Aggressive Entity. A Case Report and Review of the Literature. 61
28064232 2017
23
Genital melanoma: prognosis factors and treatment modality. 61
27365105 2016
24
Primary malignant melanoma of cervix and vagina. 61
27668208 2016
25
Evaluation of the local carcinogenic potential of mesh used in the treatment of female stress urinary incontinence. 61
26864666 2016
26
Surgical Management and Prognostic Factors of Vulvovaginal Melanoma. 61
27030881 2016
27
Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. 61
27331137 2016
28
Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohort. 61
26739672 2016
29
Nivolumab-induced organizing pneumonia in a melanoma patient. 61
26759348 2016
30
Locally Advanced Unresectable Vaginal Melanoma: Response With Anti-Programmed Death Receptor 1. 61
26704337 2016
31
C-Kit non-mutated metastatic melanoma showing positive response to Nilotinib. 61
26990482 2016
32
Non-Cutaneous Melanomas of the Genital Tract: Minimally Invasive Robotic Treatment of Primary Vaginal Melanoma-Case Report. 61
27679160 2015
33
Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study. 61
26225944 2015
34
MRI findings in primary vaginal melanoma-a report of four cases. 61
25560672 2015
35
NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands. 61
24802725 2014
36
Primary malignant melanoma of the vagina: a retrospective clinicopathologic study of 44 cases. 61
24362720 2014
37
Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence. 61
24434078 2013
38
Clinical outcome of 31 patients with primary malignant melanoma of the vagina. 61
24167668 2013
39
Treatment approach and outcomes of vaginal melanoma. 61
23945202 2013
40
Vulvar/vaginal melanoma: an updated surveillance epidemiology and end results database review, comparison with cutaneous melanoma and significance of racial disparities. 61
23765206 2013
41
Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy. 61
23480869 2013
42
A large retrospective multicenter study of vaginal melanomas: implications for new management. 61
23449321 2013
43
Round Cell Vaginal Malignant Melanoma: A rare entity. 61
23275850 2012
44
Primary Malignant Vaginal Melanoma - Case Report and Review of the Literature. 61
25258467 2012
45
Metastatic malignant melanoma of the small bowel--report of two cases. 61
20607448 2012
46
Vaginal fistula in a patient with relapsed ovarian cancer and amelanotic melanoma. 61
22593454 2012
47
[Malignant melanoma of the vagina: pejorative location]. 61
22336523 2012
48
Lumbosacral spondylodiscitis after sacral colpopexy of a sigmoid neovagina in a patient with vaginal melanoma. 61
22439780 2012
49
Topical treatment of recurrent vaginal melanoma in situ with imiquimod: A case report. 61
24371630 2012
50
Is recurrent vaginal melanoma a lethal disease? 61
21872810 2011
Sources

Variations for Malignant Skin Fibrous Histiocytoma

About this section
Sources

Expression for Malignant Skin Fibrous Histiocytoma

About this section
Search GEO for disease gene expression data for Malignant Skin Fibrous Histiocytoma.
Sources

Pathways for Malignant Skin Fibrous Histiocytoma

About this section

Pathways related to Malignant Skin Fibrous Histiocytoma according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.12 NRAS IFNA2 HRAS GNAQ GNA11
2
DAG and IP3 signaling 65
Show member pathways
 12.91 NRAS HRAS GNAQ GNA11
3
Phospholipase-C Pathway 63
Show member pathways
 12.89 NRAS KIT HRAS GNA11
4
p70S6K Signaling 63
Show member pathways
 12.88 NRAS KIT HRAS GNA11
5
PI3K-Akt signaling pathway 36
Show member pathways
 12.81 NRAS KIT IFNA2 HRAS
6
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 12.81 NRAS IFNA2 HRAS GNAQ GNA11
7
CCR5 Pathway in Macrophages 63
Show member pathways
 12.71 NRAS HRAS GNAQ GNA11
8
Human cytomegalovirus infection 36
Show member pathways
 12.65 NRAS IFNA2 HRAS GNAQ GNA11
9
Circadian entrainment 36
Show member pathways
 12.61 NRAS HRAS GNAQ GNA11
10
Aldosterone synthesis and secretion 36
Show member pathways
 12.6 NRAS KIT HRAS GNAQ GNA11
11
Ras signaling pathway 36
Show member pathways
 12.57 NRAS KIT HRAS GNAQ
12
Development Angiotensin activation of ERK 23
Show member pathways
 12.53 NRAS KIT HRAS GNAQ GNA11
13
Relaxin signaling pathway 36
Show member pathways
 12.47 NRAS HRAS GNAQ GNA11
14
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.44 NRAS HRAS GNAQ GNA11
15
Pathways in cancer 36
12.36 NRAS KIT IFNA2 HRAS GNAQ GNA11
16
Oxytocin signaling pathway 36
Show member pathways
 12.27 NRAS HRAS GNAQ GNA11
17
Phospholipase D signaling pathway 36
Show member pathways
 12.25 NRAS KIT HRAS
18
Development A3 receptor signaling 23
Show member pathways
 12.17 HRAS GNAQ GNA11
19
Apelin signaling pathway 36
11.94 NRAS HRAS GNAQ
20
Development A2B receptor- action via G-protein alpha s 23
Show member pathways
 11.88 HRAS GNAQ GNA11
21
Translation Translation regulation by Alpha-1 adrenergic receptors 23
Show member pathways
 11.86 HRAS GNAQ GNA11
22
Sphingolipid signaling pathway 36
11.85 NRAS HRAS GNAQ
23
Serotonergic synapse 36
11.83 NRAS HRAS GNAQ
24
UVA-Induced MAPK Signaling 63
Show member pathways
 11.82 NRAS HRAS GNAQ GNA11
25
MAP Kinase Signaling 4
11.81 NRAS HRAS GNAQ
26
Long-term potentiation 36
Show member pathways
 11.78 NRAS HRAS GNAQ
27
VEGF Pathway (Tocris) 60
Show member pathways
 11.65 NRAS KIT HRAS
28
G-protein signaling_RhoA regulation pathway 23
11.53 NRAS HRAS GNAQ GNA11
29
Central carbon metabolism in cancer 36
11.52 NRAS KIT HRAS
30
Gap junction 36
11.5 NRAS HRAS GNAQ GNA11
31
LPA receptor mediated events 1
11.47 HRAS GNAQ GNA11
32
Vemurafenib Pathway, Pharmacodynamics 60
11.33 NRAS HRAS
33
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 23
11.29 GNAQ GNA11
34
Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics 60
11.27 NRAS HRAS
35
CFTR-dependent regulation of ion channels in Airway Epithelium (norm and CF) 23
11.23 GNAQ GNA11
36
Arf6 signaling events 1
11.21 GNAQ GNA11
37
BDNF-TrkB Signaling 1
11.2 NRAS HRAS
38
PI3K-AKT-mTOR signaling pathway and therapeutic opportunities 1
11.15 NRAS HRAS
39
Extracellular vesicle-mediated signaling in recipient cells 1
11.15 NRAS HRAS
40
Bisphosphonate Pathway, Pharmacodynamics 60
Show member pathways
 11.13 NRAS HRAS
41
EGFR Transactivation by Gastrin 65
Show member pathways
 11.07 NRAS HRAS
42
GnRH secretion 36
11.06 NRAS HRAS GNAQ GNA11
43
MNAR-PELP1 and Estrogen Receptor Interaction 63
11.02 NRAS HRAS
44
CD209 (DC-SIGN) signaling 65
10.99 NRAS HRAS
45
Free fatty acids regulate insulin secretion 65
Show member pathways
 10.84 GNAQ GNA11
46
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling 1
10.8 NRAS HRAS GNAQ
47
p38MAPK events 65
10.73 NRAS HRAS
48
Long-term depression 36
10.7 NRAS HRAS GNAQ GNA11
Sources

GO Terms for Malignant Skin Fibrous Histiocytoma

About this section

Cellular components related to Malignant Skin Fibrous Histiocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heterotrimeric G-protein complex GO:0005834 8.62 GNAQ GNA11

Biological processes related to Malignant Skin Fibrous Histiocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.85 NRAS KIT HRAS GPHA2 GNAQ GNA11
2 MAPK cascade GO:0000165 9.61 NRAS KIT HRAS
3 action potential GO:0001508 9.4 GNAQ GNA11
4 G protein-coupled acetylcholine receptor signaling pathway GO:0007213 9.32 GNAQ GNA11
5 positive regulation of phospholipase C activity GO:0010863 9.26 KIT HRAS
6 developmental pigmentation GO:0048066 9.16 KIT GNA11
7 phototransduction, visible light GO:0007603 8.96 GNAQ GNA11
8 entrainment of circadian clock GO:0009649 8.62 GNAQ GNA11

Molecular functions related to Malignant Skin Fibrous Histiocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTP binding GO:0005525 9.46 NRAS HRAS GNAQ GNA11
2 G-protein beta/gamma-subunit complex binding GO:0031683 9.32 GNAQ GNA11
3 guanyl nucleotide binding GO:0019001 9.26 GNAQ GNA11
4 GTPase activity GO:0003924 9.26 NRAS HRAS GNAQ GNA11
5 type 2A serotonin receptor binding GO:0031826 8.62 GNAQ GNA11
Sources

Sources for Malignant Skin Fibrous Histiocytoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....